Breaking News Instant updates and real-time market news.

TWTR

Twitter

$23.52

-0.48 (-2.00%)

, CRM

Salesforce

$72.63

2.11 (2.99%)

09:02
10/05/16
10/05
09:02
10/05/16
09:02

On The Fly: Pre-market Movers

HIGHER: Acacia Communications (ACIA), up 8.5% after issuing Q3 earnings and revenue guidance that topped consensus forecasts... Anavex Life Sciences (AVXL), up 9% after announcing a collaboration with Ariana Pharma to use Ariana's proprietary patient stratification technology to potentially accelerate ANAVEX 2-73's Phase 2/3 Alzheimer's clinical development timelines... Endurance Specialty (ENH), up 4% after agreeing to be acquired by Japan's Sompo Holdings for $93 per share in cash... Twitter (TWTR), up 3.5% after The Wall Street Journal said the company is expected to field takeover offers this week. Salesforce (CRM) is among the bidders, the sources told the Journal, adding that Alphabet (GOOG) could submit an offer and that Disney (DIS) has also been weighing a bid. UP AFTER EARNINGS: Global Payments (GPN), up 4%... Constellation Brands (STZ), up 3%... AngioDynamics (ANGO), up 2.5%. DOWN AFTER EARNINGS: Micron (MU), down 1%... Acuity Brands (AYI), down 6.7%. ALSO LOWER: Salesforce, down 4.5% after The Journal's report on the Twitter bidding process... Gigamon (GIMO), down 4% after analysts at both Raymond James and DA Davidson downgraded the stock to Neutral or equivalent ratings... Immunomedics (IMMU), down 24% after pricing an underwritten offering of 10M shares of common stock and warrants to purchase up to 10M shares of common stock with anticipated gross proceeds of $30M.

TWTR

Twitter

$23.52

-0.48 (-2.00%)

CRM

Salesforce

$72.63

2.11 (2.99%)

MU

Micron

$17.80

0.07 (0.39%)

ACIA

Acacia Communications

$102.00

2.5 (2.51%)

GIMO

Gigamon

$55.13

0.18 (0.33%)

ENH

Endurance Specialty

$87.87

22.91 (35.27%)

DIS

Disney

$92.59

0.1 (0.11%)

GOOG

Alphabet

$776.43

3.87 (0.50%)

GOOGL

Alphabet Class A

$802.79

2.41 (0.30%)

IMMU

Immunomedics

$3.28

-0.03 (-0.91%)

GPN

Global Payments

$76.44

-0.68 (-0.88%)

STZ

Constellation Brands, also tag STZ.B

$165.85

0.34 (0.21%)

ANGO

AngioDynamics

$17.30

-0.13 (-0.75%)

AYI

Acuity Brands

$255.00

-8.52 (-3.23%)

  • 05

    Oct

  • 05

    Oct

  • 05

    Oct

  • 05

    Oct

  • 05

    Oct

  • 12

    Oct

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 01

    Nov

  • 09

    Nov

  • 10

    Nov

  • 30

    Nov

  • 06

    Jan

  • 15

    Jan

  • 07

    Oct

TWTR Twitter
$23.52

-0.48 (-2.00%)

10/05/16
WEDB
10/05/16
NO CHANGE
WEDB
Outperform
Twitter worries obscuring positive trends for Salesforce, says Wedbush
Wedbush analyst Steve Koenig said his industry and partner checks don't point to any secular headwinds for Salesforce's (CRM) business, adding that the company gave several reassuring metrics on its progress in cross-selling, growing deal sizes, and expanding its large account base at its investor day event at the Dreamforce conference. At the investor day, management acknowledged conjecture about Salesforce trying to buy Twitter (TWTR), but deflected comments, with CFO Mark Hawkins suggesting that CEO Marc Benioff's Q&A session Wednesday afternoon may be a better forum for soliciting comments, noted Koenig. The analyst, who remains constructive on Salesforce as long as the company doesn't buy Twitter, keeps an Outperform rating on the shares.
10/04/16
SUSQ
10/04/16
NO CHANGE
Target $15
SUSQ
Neutral
Upside potential for Twitter takeout already captured, says Susquehanna
Susquehanna analyst Shyam Patil analyzed the potential takeout range for a Twitter buyout and believes most of the potential upside has already been captured. He sees the takeout range in the $17-$24 range and with the stock trading at $24, sees little upside. Patil recommends selling Twitter before market share losses to Snap play out as its fundamentals have deteriorated significantly since going public. Patil reiterated his Neutral rating and $15 price target on Twitter shares.
10/05/16
BOFA
10/05/16
NO CHANGE
Target $100
BOFA
Buy
Salesforce acquisition of Twitter 'quite low,' says BofA/Merrill
BofA/Merrill analyst Kash Rangan said the probability of Salesforce (CRM) acquiring Twitter (TWTR) is "quite low." The analyst does not believe Salesforce would materially dilute its shareholders with such a risky deal and expects the CEO to provide clarity on the thought process behind core software acquisitions versus media at today's Q&A session. Rangan rates Salesforce a Buy with a $100 price target on shares.
CRM Salesforce
$72.63

2.11 (2.99%)

10/03/16
BMOC
10/03/16
NO CHANGE
BMOC
Salesforce removed from US Large Cap Fundamental List at BMO Capital
MU Micron
$17.80

0.07 (0.39%)

10/05/16
SUSQ
10/05/16
NO CHANGE
Target $21
SUSQ
Positive
Micron investors should focus on DRAM fundamentals, says Susquehanna
Susquehanna analyst Mehdi Hosseini noted Micron reported better than expected Q4 results driven by higher revenues. The analyst said the company guidance is below the buy-side expectation and he believes they are still challenged by converting planar to 3D NAND. Hosseini said Micron investors should focus on improving DRAM fundamentals as the better environment bodes well for the company's minority interest income and should help free cash flow. Hosseini reiterated his Buy rating and raised his price target to $21 from $20 on Micron shares.
10/05/16
EVER
10/05/16
NO CHANGE
Target $25
EVER
Buy
Micron guidance conservative, buy on weakness, says Evercore ISI
Evercore ISI analyst CJ Muse said Micron's guidance is conservative and continues to believe there will be a DRAM shortage situation in CY17 that will drive earnings power to $2-$3 including SBC. Muse recommends adding to Micron positions on weakness and reiterates his Buy rating and $25 price target.
10/05/16
STFL
10/05/16
NO CHANGE
Target $22
STFL
Buy
Micron only at start of up cycle, says Stifel
Stifel analyst Kevin Cassidy raised his price target for Micron Technology to $22 from $20, saying the company last night delivered a "solid beat" to his expectations and the consensus forecast. The company's non-GAAP EPS guidance "has some controversy" and may cause some weakness in the shares, added Cassidy. However, he would be a buyer on the weakness, citing his view that Micron's up cycle is only at its beginning. The firm keeps its Buy rating on Micron shares.
10/05/16
COWN
10/05/16
NO CHANGE
Target $19
COWN
Outperform
Micron interesting on a pullback, says Cowen
Cowen analyst Timothy Arcuri said Micron's guidance was troubling but he still sees a positive bias as DRAM supply/demand remains the first order driver for the company and industry capital expenditure is still being diverted to 3D NAND. Arcuri believes the shares will be interesting on a pullback, but said it is hardly his favorite idea. Arcuri maintained his Outperform rating and $19 price target on Micron shares.
ACIA Acacia Communications
$102.00

2.5 (2.51%)

08/18/16
NEED
08/18/16
NO CHANGE
NEED
Nokia, Alcatel-Lucent win positive for optical component companies, says Needham
Needham analyst Alex Henderson says that Alcatel-Lucent (ALU)/Nokia (NOK) announcement of a major contract win to build over 30% share of China Mobile's (CHL) 2016-2017 new construction of optical network is also a major positive for optical component companies such as Oclaro (OCLR), NeoPhotonics (NPTN), Fabrinet (FN), Lumentum (LITE), Inphi (IPHI), and Acacia (ACIA). Henderson thinks this is likely the first of three major awards in China, which will likely result in the current sold-out conditions in the coherent optical market to stretch out well into 2017.
09/01/16
BOFA
09/01/16
NO CHANGE
Target $130
BOFA
Buy
Acacia Communications price target raised ot $130 from $88 at BofA/Merrill
BofA/Merrill analyst Tal Llani raised Acacia Communications' price target to $130 from $88 to reflect potential share gains and TAM expansion. The analyst remains constructive on shares despite recent strength given product superiority, sales growth, and potential upside to Street estimates. Llani rates Acacia a Buy.
09/09/16
DBAB
09/09/16
NO CHANGE
Target $125
DBAB
Buy
Acacia Communications price target raised to $125 from $90 at Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath raised his price target for Acacia Communications to $125 from $90 after joining the company's CEO and CFO in a non-deal roadshow. The analyst sees "little risk" to Q3 estimates given solid near-term order visibility in Datacenter Optical and China Metro build outs. The consensus view of Acacia's total addressable market at $4B is conservative and does not factor in up-sell into a $1B-$2B 100G Switching and Routing market, Bhagavath tells investors in a research note. He reiterates a Buy rating on the shares. Acacia closed yesterday down $2.31 to $117.89.
09/06/16
NEED
09/06/16
NO CHANGE
Target $20
NEED
Strong Buy
Needham remains a buyer of NeoPhotonics ahead of analyst day
Needham analyst Alex Henderson believes NeoPhotonics (NPTN) is "exceptionally well positioned" for strong results over the next 3-4 quarters. The analyst "aggressively recommends" investors Buy NeoPhotonics' shares before the company's analyst day on September 8. Further, Henderson thinks Acacia's (ACIA) over $4B market cap will likely drive them to be acquisitive, and notes that it may seek to reduce costs as a percent of revenues by a potential acquisition of, for example, NeoPhotonics or Oclaro (OCLR). He reiterates a Strong Buy rating and $20 price target on NeoPhotonics' shares.
GIMO Gigamon
$55.13

0.18 (0.33%)

10/05/16
RAJA
10/05/16
DOWNGRADE
RAJA
Market Perform
Gigamon downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Simon Leopold downgraded Gigamon to Market Perform citing valuation and concerns over slowing in the security market. Potential upside from the company's new hybrid cloud solution will take time to materialize, Leopold tells investors in a research note. He believes Gigamon remains a growth story, but finds the stock fairly valued at current levels.
09/14/16
WBLR
09/14/16
NO CHANGE
WBLR
Outperform
Gigamon business momentum remains strong, says William Blair
After hosting investor meetings with Gigamon CEO Paul Hooper, William Blair analyst Jason Ader believes the company's business momentum "remains strong and unyielding." Street expectations have Gigamon's top-line growth decelerating to 20% in 2017 from 40% in 2016, which creates "meaningful opportunity for upside," Ader tells investors in a research note. He keeps an Outperform rating on the shares.
10/05/16
DADA
10/05/16
DOWNGRADE
DADA
Neutral
Gigamon downgraded to Neutral from Buy at DA Davidson
10/05/16
DADA
10/05/16
DOWNGRADE
Target $59
DADA
Neutral
Gigamon downgraded to Neutral on valuation at DA Davidson
As previously reported, DA Davidson downgraded Gigamon to Neutral from Buy. Analyst Mark Kelleher reduced his rating due to valuation and raised his price target to $59 from $54 on shares. Note that Gigamon was also downgraded at Raymond James this morning to Market Perform.
ENH Endurance Specialty
$87.87

22.91 (35.27%)

07/11/16
KBWI
07/11/16
UPGRADE
KBWI
Outperform
Endurance Specialty upgraded to Outperform at Keefe Bruyette
Keefe Bruyette upgraded Endurance Specialty Holdings to Outperform from Market Perform with a $79 price target on a transfer of coverage. The firm views the company's transformational story as compelling and highlights Endurance's recent margin improvement.
DIS Disney
$92.59

0.1 (0.11%)

09/27/16
SBSH
09/27/16
NO CHANGE
Target $16
SBSH
Neutral
Citi sees 40% downside in Twitter with no takeover bid
Citi analyst Mark May believes Twitter's (TWTR) risk/reward skews to the downside following the recent rally in the shares. A buyout of the company carries "strategic rationale for certain companies," but Twitter's "struggles and steep valuation" make a deal at a meaningful premium less likely, May tells investors in a research note. A takeover at $26 per share looks aggressive, May contends. He believes the stock could retest the lows of late May, representing 40% downside from current levels, should an acquisition offer not materialize. The analyst keeps a Neutral rating on Twitter with a $16 price target. The shares closed yesterday up 75c to $23.37 following reports that Disney (DIS) may be joining the list of potential acquires that already includes Alphabet (GOOG) and Salesforce (CRM).
09/28/16
SBSH
09/28/16
NO CHANGE
SBSH
Buy
Citi hopes Disney does not acquire Twitter
Citi analyst Jason Bazinet lays out four reasons for why he doesn't like Disney (DIS) pursuing an acquisition of Twitter (TWTR). Going back 15 years, the analyst can't think of a single web-based property that was successfully acquired by a traditional media firm. Two, he calls Twitter trends "troubling." Three, Bazinet estimates a cash offer would lower Disney's stock by $5 per share while an equity offer would drop its stock by $9. Four, the analyst feels it is unclear how Disney's content will help Twitter. Bazinet thinks both Yahoo (YHOO) and Twitter lost "significant money" when they streamed NFL content over the web. The analyst hopes Twitter is acquired by somebody other than Disney. He keeps a Buy rating on Disney shares. Both Loop Capital and Mizuho this morning downgraded Twitter to sell ratings.
09/26/16
09/26/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Drexel Hamilton with analyst Tony Wible saying he believes a large step up in NBA costs, incremental subscribers losses, difficult studio comps, a riskier studio slate, and Shanghai cost pressures will weigh on fiscal 2017. 2. Twitter (TWTR) downgraded to Underperform from Perform at Oppenheimer with analyst Jason Helfstein saying a media company is the most likely acquirer of Twitter and would not pay meaningfully more than the valuation implied by our price target. 3. RetailMeNot (SALE) downgraded to Sell from Hold at Stifel with analyst Scott Devitt saying third party data indicates that the company's traffic trends have deteriorated recently. 4. Finish Line (FINL) downgraded to Neutral from Buy at Buckingham with the firm's analyst believing shares will be range bound in medium term due to high comp expectations, cost savings will be offset by incentive compensation and other investments, and less compelling valuation. 5. NetApp (NTAP) downgraded to Sell from Hold at Deutsche Bank with analyst Sherri Scribner saying secular challenges in the storage market are not reflected in NetApp's current valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/16
UBSW
09/26/16
NO CHANGE
Target $92
UBSW
Neutral
Consumer satisfaction with competitors has caught up to Netflix, says UBS
UBS analyst Doug Mitchelson said that the firm's Evidence Lab survey indicated that U.S. consumer satisfaction with Amazon Prime Video (AMZN) and Hulu - the joint venture owned by Time Warner (TWX), Comcast (CMCSA), 21st Century Fox (FOXA), and Disney (DIS) - has now caught up to Netflix (NFLX), advising that investors should "continue to monitor competitive threats closely" as Netflix leads the category but demand for consumer media time, attention and wallet has intensified. The analyst, who added that Netflix's "pricing power remains unclear" based on the firm's survey work, keeps a Neutral rating and $92 price target on Netflix shares.
GOOG Alphabet
$776.43

3.87 (0.50%)

09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
Wedbush analyst James Dix downgraded Alphabet to Underperform and lowered his price target on shares to $700 on concerns the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive.
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
09/28/16
MZHO
09/28/16
DOWNGRADE
Target $15
MZHO
Underperform
Mizuho cuts Twitter to Underperform with $15 price target
Mizuho analyst Neil Doshi downgraded Twitter to Underperform from Neutral based on valuation. The shares are up 45% since the company reported Q2 results, primarily driven by potential buyout comments in media reports, Doshi tells investors in a research note. The stock at current levels is overvalued as Twitter's business fundamentals "have deteriorated significantly" over the past 12 months, the analyst contends. Doshi believes many of the M&A scenarios are unlikely to play out. He puts potential acquirers Salesforce (CRM) and Alphabet (GOOG, GOOGL) in the "maybe" camp, but he still has some reservations about these deals happening. The analyst believes investors of both companies would view a buyout of Twitter as negative. Doshi keeps a $15 price target for Twitter shares. The stock closed yesterday up 35c to $23.72. Loop Capital this morning also downgraded Twitter to Sell.
GOOGL Alphabet Class A
$802.79

2.41 (0.30%)

09/30/16
RBCM
09/30/16
NO CHANGE
RBCM
Street underestimating Google growth outlook, says RBC Capital
RBC Capital analyst Mark Mahaney expects Google to end 2016 with "up to 20% growth," versus the Street's outlook of mid teen percentage level growth. Mahaney says that Google's growth should be boosted by "ongoing Search innovations, rising Mobile CPCs, and the growing impact of YouTube, Play & Cloud." He thinks that YouTube's revenue is growing at a 30%-40% clip. Mahaney raised his price target on the stock to $1,025 from $1,000 and keeps an Outperform rating on the shares.
IMMU Immunomedics
$3.28

-0.03 (-0.91%)

06/21/16
WELS
06/21/16
DOWNGRADE
WELS
Market Perform
Immunomedics downgraded to Market Perform from Outperform at Wells Fargo
05/06/16
JEFF
05/06/16
UPGRADE
Target $5
JEFF
Buy
Immunomedics upgraded to Buy from Hold at Jefferies
Jefferies analyst Chris Howerton upgraded Immunomedics to Buy saying IMMU-132 continues to demonstrate impressive clinical data in solid tumors. The analyst sees a greater likelihood of Immunomedics securing a partner for the asset following recent data. He raised his price target for the shares to $5.00 from $1.50.
03/15/16
WELS
03/15/16
NO CHANGE
WELS
Immunomedics PANCRIT trial failure was expected, says Wells Fargo
After Immunomedics late yesterday announced that it's terminating its Phase 3 PANCRIT-1 trial, Wells Fargo says that this development was expected, given the trial's high clinical hurdle and invalidated target. Wells cut its price target on the stock to $3-$3.50 from $4-$4.50 in response to the news. However, the firm continues to believe that the company can find a partner for its IMMU132 drug, and it keeps an Outperform rating on the shares.
02/05/16
WELS
02/05/16
UPGRADE
WELS
Outperform
Immunomedics upgraded to Outperform from Market Perform at Wells Fargo
GPN Global Payments
$76.44

-0.68 (-0.88%)

09/15/16
GSCO
09/15/16
UPGRADE
Target $88
GSCO
Buy
Global Payments upgraded to Buy from Neutral at Goldman
Goldman Sachs analyst James Schneider upgraded Global Payments to Buy saying the company's revenue growth is likely to exceed 10% over the next two years, which is ahead of consensus and management's high-single digit growth target. Cost and revenue synergies from the Heartland acquisition are likely to exceed investor expectations, Schneider tells investors in a research note. He upped his price target for the shares to $88 from $80.
07/22/16
SBSH
07/22/16
NO CHANGE
Target $89
SBSH
Buy
Global Payments price target raised to $89 from $78 at Citi
Citi analyst Ashwin Shirvaikar raised his price target for Global Payments to $89 saying the company is "likely to easily post upside to acquisition synergy assumptions." The analyst likes the stock at these levels and keeps a Buy rating on the name.
08/18/16
OPCO
08/18/16
NO CHANGE
OPCO
Outperform
Oppenheimer encouraged by Global Payments growth opportunity
Following a visit to the company's headquarters, Oppenheimer analyst Glenn Greene says he remains encouraged by Global Payments' intermediate and long-term growth and margin opportunity. The Heartland integration appears ahead of schedule, and the combined entity has already realized sales success, the analyst tells investors in a research note. Further, Greene believes the company's 2017 guidance appears reasonable, if not conservative, and would not preclude upside to its Heartland synergy targets. He reiterates an Outperform rating on the shares.
07/12/16
DBAB
07/12/16
NO CHANGE
Target $79
DBAB
Buy
Global Payments price target raised to $79 from $72 at Deutsche Bank
Deutsche Bank analyst Bryan Keane raised his price target for Global Payments to $79 saying estimates continue to have an upward bias. The acquisition of Heartland could drive further upside, the analyst contends. He keeps a Buy rating on the shares.
STZ Constellation Brands, also tag STZ.B
$165.85

0.34 (0.21%)

09/15/16
FBCO
09/15/16
INITIATION
Target $178
FBCO
Neutral
Constellation Brands initiated with a Neutral at Credit Suisse
Credit Suisse analyst Laurent Grandet initiated coverage on Constellation Brands with a Neutral and a $178 price target saying high expectations are built into shares.
09/15/16
FBCO
09/15/16
INITIATION
FBCO
Neutral
Constellation Brands initiated with a Neutral at Credit Suisse
09/28/16
RBCM
09/28/16
NO CHANGE
RBCM
Constellation Brands removed from Focus List at RBC Capital
RBC Capital analyst Nik Modi, noting that Constellation Brands' stock is up 16% this year, thinks that the stock could pause in the near-term "around the company's results." He notes that analysts are already expecting the company to report beat and raise results. Modi keeps a $181 price target and Outperform rating on the shares, but he removed the stock from the firm's Focus List.
09/16/16
09/16/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GoPro (GPRO) initiated with a Buy at BofA/Merrill. 2. JetBlue (JBLU) initiated with an Outperform at Imperial Capital. 3. PepsiCo (PEP), Dr Pepper Snapple (DPS), and Monster Beverage (MNST) were initiated with an Outperform at Credit Suisse, while the firm initiated Boston Beer (SAM) with an Underperform. Credit Suisse also initiated Coca-Cola (KO) and Constellation Brands (STZ) with a Neutral. 4. lululemon (LULU) initiated with a Positive at Susquehanna. 5. Target (TGT) coverage assumed with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ANGO AngioDynamics
$17.30

-0.13 (-0.75%)

04/05/16
ADAM
04/05/16
DOWNGRADE
ADAM
Hold
AngioDynamics downgraded to Hold from Buy at Canaccord
11/10/15
11/10/15
DOWNGRADE

Market Perform
AngioDynamics downgraded to Market Perform from Outperform at Raymond James
As previously reported, Raymond James downgraded AngioDynamics to Market Perform from Outperform. Analyst Jayson Bedford said he is skeptical of the second half 2016 ramp implied by guidance and does not see a catalyst for near-term multiple expansion. Bedford does not see any quick fixes and struggles to fine a path leading to outperformance.
04/08/16
PIPR
04/08/16
INITIATION
Target $12
PIPR
Neutral
AngioDynamics assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Brooks West assumed coverage of AngioDynamics with a Neutral rating and $12 price target. The company's investment is clouded in the near-term given the recent management changes, West tells investors in a research note following AngioDynamics' Q3 results.
11/10/15
11/10/15
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AngioDynamics (ANGO) downgraded to Market Perform from Outperform at Raymond James... Arch Coal (ACI) downgraded to Neutral from Buy at Sterne Agee CRT... Autodesk (ADSK) downgraded to Equal Weight from Overweight at Morgan Stanley... Bitauto (BITA) downgraded to Underperform from Outperform at CLSA... Black Knight Financial (BKFS) downgraded to Neutral from Buy at Monness Crespi... CEVA (CEVA) downgraded to Hold from Buy at Wunderlich... CIRCOR (CIR) downgraded to Accumulate from Speculative Buy at Seaport Global... Compania Cervecerias (CCU) downgraded to Hold from Buy at Deutsche Bank... CyberArk (CYBR) downgraded to Neutral at BofA/Merrill... Dean Foods (DF) downgraded to Underperform from Neutral at Credit Suisse... Dollar General (DG) downgraded to Peer Perform from Outperform at Wolfe Research... Dr. Reddy's Labs (RDY) downgraded to Neutral from Buy at Citi... EnerSys (ENS) downgraded to Neutral from Buy at CL King... Ensco (ESV) downgraded to Sell from Neutral at Clarksons Platou... Evercore Partners (EVR) downgraded to Neutral from Positive at Susquehanna... Fidelity & Guaranty Life (FGL) downgraded to Neutral from Outperform at Macquarie... Foot Locker (FL) downgraded to Neutral from Buy at Buckingham... GulfMark Offshore (GLF) downgraded to Sector Perform from Outperform at Iberia... Jamba (JMBA) downgraded to Neutral from Buy at Dougherty... Jazz Pharmaceuticals (JAZZ) downgraded to Neutral from Buy at Mizuho... King Digital (KING) downgraded to Equal Weight from Overweight at Morgan Stanley... MRC Global (MRC) downgraded to Hold from Buy at Maxim... Plum Creek Timber (PCL) downgraded to Neutral from Overweight at JPMorgan... Popeyes (PLKI) downgraded to Neutral following checks at Longbow... Provident Financial (PFS) downgraded to Neutral from Overweight at Piper Jaffray... RigNet (RNET) downgraded to Neutral from Buy at Sidoti... SMART Technologies (SMT) downgraded to Underperformer from Sector Performer at CIBC... Sealed Air (SEE) downgraded to Neutral from Outperform at Macquarie... Tesco (TSCDY) downgraded to Hold from Buy at Deutsche Bank... Textura (TXTR) downgraded on guidance cut, investment profile change at Oppenheimer... WM Morrison (MRWSY) downgraded to Sell from Hold at Deutsche Bank... WidePoint (WYY) downgraded to Hold from Buy at Craig-Hallum.
AYI Acuity Brands
$255.00

-8.52 (-3.23%)

09/30/16
WILL
09/30/16
INITIATION
Target $306
WILL
Buy
Acuity Brands initiated with a Buy at Williams Capital
Williams Capital analyst Cynthia Motz initiated Acuity Brands with a Buy and a $306 price target.
09/30/16
ROTH
09/30/16
NO CHANGE
Target $275
ROTH
Neutral
Roth Capital cautious on Acuity Brands ahead of earnings after survey
Roth Capital analyst Craig Irwin said he is more cautious on Acuity Brands ahead of the company's earnings report next week after the firm's lighting market survey indicated weaker activity than anticipated. The analyst, who thinks expectations for Acuity are high, keeps his $275 price target and Neutral rating on the stock.
09/30/16
COWN
09/30/16
NO CHANGE
Target $285
COWN
Outperform
Cowen sees another strong quarter of growth for Acuity Brands
Cowen analyst Jeffrey Osborne predicted that Acuity Brands will report another strong quarter of growth in Q4, citing his conversations with lighting industry participants. The analyst, who thinks the company's position in the U.S. non-residential lighting space is strengthening and that is margins are improving, keeps an Outperform rating and $285 price target on the stock ahead of its earnings report, due on October 5.
09/08/16
GSCO
09/08/16
NO CHANGE
GSCO
Goldman's Focus List changes
Goldman added Acuity Brands (AYI) & Facebook (FB) to the Focus List and removed Biogen (BIIB), BorgWarner (BWA), Monsanto (MON), and Grainger (GWW). The bank commented Acuity is a beneficiary of the Low Carbon Economy and said Facebook ranks as a low asset-light tech disruptor that is able to leverage its world-leading user base and mobile users to monetize long-term growth.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.